keyword
https://read.qxmd.com/read/38630301/-gastrointestinal-disorders-in-hyperkinetic-movement-disorders-and-ataxia
#1
REVIEW
Inga Claus, Tobias Warnecke
Disorders of the gastrointestinal tract in patients suffering from hypokinetic movement disorders, and in particular Parkinson's disease, have increasingly been the subject of more intensive neuromedical research. So far, few data are available for patients with hyperkinetic movement disorders and ataxias. This review article summarizes the currently available and relevant publications on this topic. The particular focus is on essential tremor, restless legs syndrome, Huntington's disease and the group of hereditary ataxias...
April 17, 2024: Der Nervenarzt
https://read.qxmd.com/read/38627751/longitudinal-alterations-in-brain-perfusion-and-vascular-reactivity-in-the-zq175dn-mouse-model-of-huntington-s-disease
#2
JOURNAL ARTICLE
Tamara Vasilkovska, Somaie Salajeghe, Verdi Vanreusel, Johan Van Audekerke, Marlies Verschuuren, Lydiane Hirschler, Jan Warnking, Isabel Pintelon, Dorian Pustina, Roger Cachope, Ladislav Mrzljak, Ignacio Muñoz-Sanjuan, Emmanuel L Barbier, Winnok H De Vos, Annemie Van der Linden, Marleen Verhoye
BACKGROUND: Huntington's disease (HD) is marked by a CAG-repeat expansion in the huntingtin gene that causes neuronal dysfunction and loss, affecting mainly the striatum and the cortex. Alterations in the neurovascular coupling system have been shown to lead to dysregulated energy supply to brain regions in several neurological diseases, including HD, which could potentially trigger the process of neurodegeneration. In particular, it has been observed in cross-sectional human HD studies that vascular alterations are associated to impaired cerebral blood flow (CBF)...
April 16, 2024: Journal of Biomedical Science
https://read.qxmd.com/read/38627749/health-state-utility-estimates-for-value-assessments-of-novel-treatments-in-huntington-s-disease-a-systematic-literature-review
#3
REVIEW
Ruta Sawant, Kyle Paret, Jennifer Petrillo, Aaron Koenig, Sorrel Wolowacz, Naoko Ronquest, Hugh Rickards
BACKGROUND: Huntington's disease (HD) is a progressive neurodegenerative disease with a devastating impact on patients and their families. Quantifying how treatments affect patient outcomes is critical for informing reimbursement decisions. Many countries mandate a formal value assessment in which the treatment benefit is measured as quality-adjusted life-years, calculated with the use of utility estimates that reflect respondents' preferences for health states. OBJECTIVE: To summarize published health state utility data in HD and identify gaps and uncertainties in the data available that could be used to inform value assessments...
April 16, 2024: Health and Quality of Life Outcomes
https://read.qxmd.com/read/38627228/clinical-and-genetic-characteristics-associated-with-survival-outcome-in-late-onset-huntington-s-disease-in-south-korea
#4
JOURNAL ARTICLE
Yun Su Hwang, Sungyang Jo, Gu-Hwan Kim, Jee-Young Lee, Ho-Sung Ryu, Eungseok Oh, Seung-Hwan Lee, Young Seo Kim, Sun Ju Chung
BACKGROUND AND PURPOSE: The onset of Huntington's disease (HD) usually occurs before the age of 50 years, and the median survival time from onset is 15 years. We investigated survival in patients with late-onset HD (LoHD) (age at onset ≥60 years) and the associations of the number of mutant CAG repeats and age at onset (AAO) with survival in patients with HD. METHODS: Patients with genetically confirmed HD at six referral centers in South Korea between 2000 and 2020 were analyzed retrospectively...
April 2, 2024: Journal of Clinical Neurology
https://read.qxmd.com/read/38625861/immunotherapy-utilization-patterns-in-patients-with-advanced-cancer-and-autoimmune-disease
#5
JOURNAL ARTICLE
Huaqi Li, Scott Huntington, Cary Gross, Shi-Yi Wang
PURPOSE: Immunotherapy has been shown to improve cancer survival, but there are no consensus guidelines to inform use in patients with both cancer and autoimmune disease (AD). We sought to examine immunotherapy utilization patterns between cancer patients with and without AD. PATIENTS AND METHODS: This retrospective cohort study utilized data from a de-identified nationwide oncology database. Patients diagnosed with advanced melanoma, non-small cell lung cancer, and renal cell carcinoma were included...
2024: PloS One
https://read.qxmd.com/read/38623850/living-leading-medicine-a-two-tiered-leadership-development-programme-for-family-medicine-residents
#6
JOURNAL ARTICLE
Jeffrey S Cook, Briana Money, Daniel Dyer, Georgianna Whiteley, Mark K Huntington
BACKGROUND: There is increasing awareness of the necessity and importance for physician leadership in health care. Despite this, formal leadership training is not widespread in medical education. APPROACH: We describe the structure, curriculum and development of a robust two-tiered leadership development programme within a community-based family medicine residency programme. Living, Leading & Medicine (LLM, tier 1) consists of nine 2.5-h discussion-based training sessions occurring thrice annually...
April 16, 2024: Clinical Teacher
https://read.qxmd.com/read/38623278/gangliosides-as-therapeutic-targets-for-neurodegenerative-diseases
#7
REVIEW
Orhan Kerim Inci, Hande Basırlı, Melike Can, Selman Yanbul, Volkan Seyrantepe
Gangliosides, sialic acid-containing glycosphingolipids, are abundant in cell membranes and primarily involved in controlling cell signaling and cell communication. The altered ganglioside pattern has been demonstrated in several neurodegenerative diseases, characterized during early-onset or infancy, emphasizing the significance of gangliosides in the brain. Enzymes required for the biosynthesis of gangliosides are linked to several devastating neurological disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegia (HSP)...
2024: Journal of Lipids
https://read.qxmd.com/read/38621750/formation-of-supplementary-metal-binding-centers-in-proteins-under-stress-conditions
#8
REVIEW
Olga V Kosmachevskaya, Natalia N Novikova, Sergey N Yakunin, Alexey F Topunov
In many proteins, supplementary metal-binding centers appear under stress conditions. They are known as aberrant or atypical sites. Physico-chemical properties of proteins are significantly changed after such metal binding, and very stable protein aggregates are formed, in which metals act as "cross-linking" agents. Supplementary metal-binding centers in proteins often arise as a result of posttranslational modifications caused by reactive oxygen and nitrogen species and reactive carbonyl compounds. New chemical groups formed as a result of these modifications can act as ligands for binding metal ions...
January 2024: Biochemistry. Biokhimii︠a︡
https://read.qxmd.com/read/38619493/efficient-electrochemical-microsensor-for-the-simultaneous-measurement-of-hydrogen-peroxide-and-ascorbic-acid-in-living-brains
#9
JOURNAL ARTICLE
Qiuyue Chen, Ruizhi Lin, Wenhui Wang, Yimei Zuo, Yi Zhuo, Yanyan Yu, Shu Chen, Hui Gu
Hydrogen peroxide (H2 O2 ) and ascorbic acid (AA), acting as two significant indicative species, correlate with the oxidative stress status in living brains, which have historically been considered to be involved mainly in neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, and Parkinson's disease (PD). The development of efficient biosensors for the simultaneous measurement of their levels in living brains is vital to understand their roles played in the brain and their interactive relationship in the progress of these diseases...
April 15, 2024: Analytical Chemistry
https://read.qxmd.com/read/38619318/discovery-of-a-pocket-network-on-the-domain-5-of-the-trkb-receptor-a-potential-new-target-in-the-quest-for-the-new-ligands
#10
JOURNAL ARTICLE
Mirjana Antonijevic, Jana Sopkova-de Oliveira Santos, Patrick Dallemagne, Christophe Rochais
The important role that the neurotrophin tyrosine kinase receptor - TrkB has in the pathogenesis of several neurodegenerative conditions such are Alzheimer's disease, Parkinson's disease, Huntington's disease, has been well described. This shouldn't be a surprise, since in the physiological conditions, once activated by brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5), the TrkB receptor promotes neuronal survival, differentiation and synaptic function. Considering that the natural ligands for TrkB receptor are large proteins, it is a challenge to discover small molecule capable to mimic their effects...
April 15, 2024: Molecular Informatics
https://read.qxmd.com/read/38617831/the-first-case-of-huntington-s-disease-like-2-in-mali-west-africa
#11
Abdoulaye Bocoum, Madani Ouologuem, Lassana Cissé, Fahmida Essop, Souleymane Dit Papa Coulibaly, Nadine Botha, Cheick A K Cissé, Alassane Dit Baneye Maiga, Amanda Krause, Guida Landouré
BACKGROUND: Huntington's disease like 2 (HDL2) has been reported exclusively in patients with African ancestry, mostly originating from South Africa. CASE REPORT: We report three patients in Mali including a proband and his two children who have been examined by neurologists and psychiatrists after giving consent. They were aged between 28 and 56 years old. Psychiatric symptoms were predominant in the two younger patients while the father presented mainly with motor symptoms...
2024: Tremor and Other Hyperkinetic Movements
https://read.qxmd.com/read/38617022/cross-sectional-analysis-of-exome-sequencing-diagnosis-in-patients-with-neurologic-phenotypes-facing-barriers-to-clinical-testing
#12
JOURNAL ARTICLE
Sonya Watson, Kathie J Ngo, Hannah A Stevens, Darice Y Wong, Jihye Kim, Yongjun Song, Beomman Han, Seong-In Hyun, Rin Khang, Seung Woo Ryu, Eugene Lee, Gohun Seo, Hane Lee, Clara Lajonchere, Brent L Fogel
BACKGROUND AND OBJECTIVES: Exome sequencing (ES) demonstrates a 20-50 percent diagnostic yield for patients with a suspected monogenic neurologic disease. Despite the proven efficacy in achieving a diagnosis for such patients, multiple barriers for obtaining exome sequencing remain. This study set out to assess the efficacy of ES in patients with primary neurologic phenotypes who were appropriate candidates for testing but had been unable to pursue clinical testing. METHODS: A total of 297 patients were identified from the UCLA Clinical Neurogenomics Research Center Biobank, and ES was performed, including bioinformatic assessment of copy number variation and repeat expansions...
June 2024: Neurology. Genetics
https://read.qxmd.com/read/38615323/polyglutamine-disease-proteins-commonalities-and-differences-in-interaction-profiles-and-pathological-effects
#13
REVIEW
Megan Bonsor, Orchid Ammar, Sigrid Schnoegl, Erich E Wanker, Eduardo Silva Ramos
Currently, nine polyglutamine (polyQ) expansion diseases are known. They include spinocerebellar ataxias (SCA1, 2, 3, 6, 7, 17), spinal and bulbar muscular atrophy (SBMA), dentatorubral-pallidoluysian atrophy (DRPLA), and Huntington's disease (HD). At the root of these neurodegenerative diseases are trinucleotide repeat mutations in coding regions of different genes, which lead to the production of proteins with elongated polyQ tracts. While the causative proteins differ in structure and molecular mass, the expanded polyQ domains drive pathogenesis in all these diseases...
April 14, 2024: Proteomics
https://read.qxmd.com/read/38614929/a-developmental-component-to-huntington-s-disease
#14
REVIEW
L Ratié, S Humbert
Huntington's disease is a dominantly inherited disorder characterized by the dysfunction and death of cortical and striatal neurons. Striatal degeneration in Huntington's disease is due, at least in part, to defective cortical signalling to the striatum. Although Huntington's disease generally manifests at the adult stage, mouse and neuroimaging studies of presymptomatic mutation carriers suggest that it may affect neurodevelopment. In support of this notion, the development of the cortex is altered in mice with Huntington's disease and the foetuses of human Huntington's disease gene carriers...
April 12, 2024: Revue Neurologique
https://read.qxmd.com/read/38614367/treating-alzheimer-s-disease-using-nanoparticle-mediated-drug-delivery-strategies-systems
#15
REVIEW
Aryan Kia Roghani, Ricardo Isaiah Garcia, Ali Roghani, Aananya Reddy, Sachi Khemka, Ruhananhad P Reddy, Vasanthkumar Pattoor, Michael Jacob, P Hemachandra Reddy, Ujala Sehar
The administration of promising medications for the treatment of neurodegenerative disorders (NDDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) is significantly hampered by the blood-brain barrier (BBB). Nanotechnology has recently come to light as a viable strategy for overcoming this obstacle and improving drug delivery to the brain. With a focus on current developments and prospects, this review article examines the use of nanoparticles to overcome the BBB constraints to improve drug therapy for AD The potential for several nanoparticle-based approaches, such as those utilizing lipid-based, polymeric, and inorganic nanoparticles, to enhance drug transport across the BBB are highlighted...
April 12, 2024: Ageing Research Reviews
https://read.qxmd.com/read/38614044/influence-of-anosognosia-on-patient-reported-outcomes-for-psychiatric-symptoms-and-quality-of-life-in-huntington-s-disease
#16
JOURNAL ARTICLE
David A Isaacs, Kaitlyn R Hay, Jennifer Hoadley, Katherine E McDonell, Amy E Brown, Amy Wynn, Daniel O Claassen, Jessie Gibson
INTRODUCTION: Anosognosia, defined as reduced awareness of one's deficit or symptom, is common in Huntington's disease (HD) and detectable at each disease stage. The impact of anosognosia on self-reporting in HD populations is critical to understand given growing use of patient-reported outcomes in HD clinical care and research. We aimed to determine the influence of anosognosia on patient-reported outcome measures assessing psychiatric symptoms and quality of life in HD. METHODS: We enrolled HD patients to complete a battery of patient-reported and rater-administered measures, including the Anosognosia Scale, at baseline and 6 months later...
April 9, 2024: Parkinsonism & related Disorders
https://read.qxmd.com/read/38612804/neuroinflammation-in-neurodegenerative-disorders-current-knowledge-and-therapeutic-implications
#17
REVIEW
Paras Mani Giri, Anurag Banerjee, Arpita Ghosal, Buddhadev Layek
Neurodegenerative disorders (NDs) have become increasingly common during the past three decades. Approximately 15% of the total population of the world is affected by some form of NDs, resulting in physical and cognitive disability. The most common NDs include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease. Although NDs are caused by a complex interaction of genetic, environmental, and lifestyle variables, neuroinflammation is known to be associated with all NDs, often leading to permanent damage to neurons of the central nervous system...
April 3, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612683/the-formation-and-function-of-the-vta-dopamine-system
#18
REVIEW
Guoqiang Hou, Mei Hao, Jiawen Duan, Ming-Hu Han
The midbrain dopamine system is a sophisticated hub that integrates diverse inputs to control multiple physiological functions, including locomotion, motivation, cognition, reward, as well as maternal and reproductive behaviors. Dopamine is a neurotransmitter that binds to G-protein-coupled receptors. Dopamine also works together with other neurotransmitters and various neuropeptides to maintain the balance of synaptic functions. The dysfunction of the dopamine system leads to several conditions, including Parkinson's disease, Huntington's disease, major depression, schizophrenia, and drug addiction...
March 30, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612657/huntington-s-disease-complex-pathogenesis-and-therapeutic-strategies
#19
REVIEW
Huichun Tong, Tianqi Yang, Shuying Xu, Xinhui Li, Li Liu, Gongke Zhou, Sitong Yang, Shurui Yin, Xiao-Jiang Li, Shihua Li
Huntington's disease (HD) arises from the abnormal expansion of CAG repeats in the huntingtin gene ( HTT ), resulting in the production of the mutant huntingtin protein (mHTT) with a polyglutamine stretch in its N-terminus. The pathogenic mechanisms underlying HD are complex and not yet fully elucidated. However, mHTT forms aggregates and accumulates abnormally in neuronal nuclei and processes, leading to disruptions in multiple cellular functions. Although there is currently no effective curative treatment for HD, significant progress has been made in developing various therapeutic strategies to treat HD...
March 29, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612544/targeting-n-methyl-d-aspartate-receptors-in-neurodegenerative-diseases
#20
REVIEW
Allison Carles, Aline Freyssin, Florent Perin-Dureau, Gilles Rubinstenn, Tangui Maurice
N -methyl-d-aspartate receptors (NMDARs) are the main class of ionotropic receptors for the excitatory neurotransmitter glutamate. They play a crucial role in the permeability of Ca2+ ions and excitatory neurotransmission in the brain. Being heteromeric receptors, they are composed of several subunits, including two obligatory GluN1 subunits (eight splice variants) and regulatory GluN2 (GluN2A~D) or GluN3 (GluN3A~B) subunits. Widely distributed in the brain, they regulate other neurotransmission systems and are therefore involved in essential functions such as synaptic transmission, learning and memory, plasticity, and excitotoxicity...
March 27, 2024: International Journal of Molecular Sciences
keyword
keyword
18527
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.